J. Blokken PhD, PharmD

New haematology reimbursements in Belgium

(BELG J HEMATOL 2020;11(7):339)

Highlights in multiple myeloma

SUMMARY

Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment modalities in both the induction and maintenance setting, to manage newly diagnosed MM ever continues. In recent years, the treatment landscape of patients with relapsed refractory multiple myeloma (RRMM) has also changed dramatically following a long list of positive phase III trials. This overview will give an update of pivotal trials in this setting (IKEMA, OPTIMISMM, CANDOR, BELLINI) as well as discusses some new emerging therapies in the field, including CAR T cell therapy, a B-cell maturation antigen T-cell engager and a novel cereblon E3 ligase modulator (CELMoD) agent.

(BELG J HEMATOL 2020;11(5):203-8)

Journal Scan

SUMMARY

In this section of the BJH, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2020;11(4):190–3)

The 35^th general annual meeting of the Belgian Hematology Society

SUMMARY

On the 14^th and 15^th of February 2020, the Belgian Hematology Society hosted their 35^th annual meeting in La Hulpe, Brussels. This year’s meeting featured scientific parallel sessions organised by the Belgian Society for Advancement of Cytometry (BSAC), the Belgian Society of Thrombosis and Haemostasis (BSTH), MolecularDiagnostics.be (MD.be) as well as a nurse symposium. In this article, we will highlight the scientific sessions presented during the BHS meeting.

(BELG J HEMATOL 2020;11(3):136–41)

Journal Scan

The goal of this new section in the BJH is to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2020;11(2):79–81)

Miscellaneous news from ASH 2019

Summary

In addition to the plethora of abstracts in the larger haematological subdomains discussed in this special issue of the BJH, ASH 2019 also featured many interesting presentations that do not fall within one of these categories. In this article we would like to address some of this ‘miscellaneous news’ from ASH 2019. In the field of venous thromboembolism (VTE), bodyweight-adjusted rivaroxaban could provide a new alternative treatment option for paediatric patients. Also with respect to VTE, the Ottawa score failed to demonstrate its predictive value for VTE recurrence in cancer patients. In addition, interesting new data were presented on the prevention of graft-versus-host-disease (GVHD) after an allogeneic transplantation. At this year’s meeting, there was also a session dedicated to disorders in the number or function of platelets in which much attention went to novel drug targets and novel drug combinations for the treatment of immune thrombocytopenia. Finally, some interesting presentations on sickle cell disease, myelofibrosis-associated anaemia and cold agglutinin disease (CAD) will be discussed in this overview.

(BELG J HEMATOL 2020;11(1):35–40)

Bispecific T-cell engagers (BiTEs) in haematological malignancies

SUMMARY

Bispecific T-cell engagers (BiTEs) are a class of immunotherapeutics that can redirect T cells to haematological malignancies. A key advantage of BiTEs over adoptive T-cell therapies, consists of the fact that a BiTE is an “off the shelf” meaning that the same product can be given to all patients. In contrast, adoptive T-cell therapies must be made from cells taken from each patient and as a result this strategy is more time consuming and potentially more expensive. The most successful BiTE to date is blinatumomab. This agent is made up of CD3 and CD19 single-chain variable regions linked by a glycine–serine linker. It binds selectively to CD3 expressing T cells and CD19 expressing B cells, leading to the formation of immune synapses between T cells and B cells. In doing so, blinatumomab redirects unstimulated cytotoxic T cells to specifically target and lyse CD19-positive B cells. Blinatumomab is currently approved for patients with relapsed/refractory and minimal residual disease positive B-cell precursor acute lymphoblastic leukaemia (B-ALL). This review will discuss the pivotal trials with this agent and will touch upon some of the additional BiTEs that are under clinical evaluation in haematological malignancies. Finally, some remaining challenges with respect to optimising the efficacy and safety of BiTEs will be addressed.

(BELG J HEMATOL 2019;10(8):332–8)